Skip to main content
Patient Guides

GLP-1 Drug Pipeline 2026-2026: Every New Weight Loss Medication in Development

Updated March 29, 2026
Fact Checked

Complete guide to the GLP-1 drug pipeline — every new weight loss medication in Phase 2-3 trials including retatrutide, survodutide, amycretin, aleniglipron, and CagriSema.

Key Takeaways

  • Wegovy HD (semaglutide 7.2mg) was FDA-approved March 19, 2026, achieving 20.7% mean weight loss.
  • Orforglipron reached 12.4% weight loss at 72 weeks in Phase 3 and launched at $149/month.
  • Retatrutide produced 28.7% weight loss in TRIUMPH-1 — the highest ever in a rigorous obesity trial.
  • CagriSema (semaglutide + cagrilintide) hit 23% weight loss; FDA NDA filed December 2025.
  • Aleniglipron showed 16.3% weight loss in Phase 2, surpassing orforglipron; Phase 3 starts H2 2026.
Illustration for: GLP-1 Drug Pipeline 2026-2026: Every New Weight Loss Medication in Development
Illustration for: GLP-1 Drug Pipeline 2026-2026: Every New Weight Loss Medication in Development

GLP-1 Drug Pipeline 2026-2027: Every New Weight Loss Medication in Development

The weight loss medication landscape is changing rapidly. Wegovy HD (semaglutide 7.2 mg) was FDA-approved on March 19, 2026, delivering 20.7% weight loss — a significant step up from standard Wegovy's 15.8%. Orforglipron — the first non-semaglutide oral GLP-1 — is awaiting FDA approval (PDUFA April 10, 2026) at an announced $149/month. Between now and 2028, at least five more GLP-1-class drugs could reach the market, including a triple-agonist that produced 28.7% weight loss and several new mechanisms that go beyond anything currently available.

This guide covers every significant drug in the GLP-1 pipeline, from those weeks away from FDA decisions to those just entering Phase 3 trials. We track what the clinical data actually shows, when each drug might realistically become available, and what it means for patients deciding whether to start treatment now or wait.

Important: Most of these medications are investigational and not yet FDA-approved. Clinical trial results do not guarantee regulatory approval, and timelines are estimates that frequently shift. We will update this page as new data emerges.

The Pipeline at a Glance

Drug Company Mechanism Route Best Weight Loss Phase Est. Availability
Wegovy HD ✅ Novo Nordisk GLP-1 agonist (high-dose semaglutide 7.2mg) Weekly injection 20.7% (STEP UP) FDA-approved April 2026 Available April 2026
Orforglipron Eli Lilly GLP-1 agonist Daily oral pill 12.4% (Phase 3 final) PDUFA April 10, 2026 Expected after approval — $149/mo announced
CagriSema Novo Nordisk GLP-1 + amylin (cagrilintide + semaglutide) Weekly injection 23% NDA filed Dec 2025 Late 2026
Retatrutide Eli Lilly Triple agonist (GLP-1/GIP/glucagon) Weekly injection 28.7% Phase 3 (TRIUMPH) 2027-2028
Survodutide Boehringer Ingelheim Dual agonist (GLP-1/glucagon) Weekly injection 18.7% Phase 3 (SYNCHRONIZE) 2028+
Amycretin (zenagamtide) Novo Nordisk GLP-1/amylin agonist Oral + injectable 22% Phase 3 initiated Q1 2026 2028-2029
Aleniglipron Structure Therapeutics Small-molecule oral GLP-1 Daily oral pill 16.3% End-of-Phase 2; Phase 3 H2 2026 2028-2029
Monthly injectables Various Various GLP-1 mechanisms Monthly injection Varies Phase 1-2 2028+

Wegovy HD is approved (April 2026). Orforglipron is pending FDA approval (PDUFA April 10, 2026). CagriSema is the next closest to market after that, with an FDA decision expected in late 2026 or 2027. The rest are in Phase 2 or Phase 3 trials with more distant timelines.

What's Changed Since 2024

For anyone who last checked the pipeline a year or two ago, here is what has shifted:

Wegovy HD (semaglutide 7.2 mg) is now FDA-approved. Approved March 19, 2026 under the National Priority Review Voucher program (54-day review), Wegovy HD delivers three times the dose of standard Wegovy. The STEP UP trial showed 20.7% mean weight loss — roughly 5 percentage points more than standard Wegovy's 15.8%. A notable new side effect is dysesthesia (tingling, numbness, burning) in 18.9% of patients. It launches in April 2026 and is intended for patients who have plateaued on or want more than standard Wegovy. See our Wegovy HD complete guide.

Orforglipron awaits FDA approval (PDUFA April 10, 2026). It is the first non-semaglutide oral GLP-1 for weight loss — and at an announced $149/month through LillyDirect, it would undercut every injectable on the market. Final Phase 3 data showed 12.4% weight loss. Insurance coverage and Medicare Bridge access will begin rolling out once the drug is approved.

Retatrutide confirmed its Phase 2 results in Phase 3. The TRIUMPH-1 trial reported 28.7% mean weight loss at 12 mg — matching Phase 2 data and confirming this is not a statistical fluke. Seven Phase 3 trials are now running or completed. This is the most effective weight loss drug ever tested in a rigorous trial.

CagriSema's NDA was filed. Novo Nordisk submitted CagriSema to the FDA in December 2025, putting it on track for a potential 2026 approval. The REDEFINE program showed 23% weight loss — substantially more than either semaglutide or cagrilintide alone.

Amycretin entered Phase 3. Novo Nordisk's GLP-1/amylin dual agonist moved into Phase 3 trials in Q1 2026 after showing 22% weight loss in early studies. Both oral and injectable formulations are being developed.

The oral GLP-1 race expanded. Aleniglipron (Structure Therapeutics) posted 16.3% weight loss at 180 mg in its ACCESS II trial — more than orforglipron — and is preparing for Phase 3. The competition for oral weight loss pills is intensifying.

Monthly injectables entered clinical development. Multiple companies are now testing once-monthly GLP-1 formulations, targeting the adherence and convenience problems that plague weekly injectables.

Drug-by-Drug Breakdown

1. Orforglipron (Eli Lilly) — PDUFA April 10, 2026

What it is: A once-daily oral GLP-1 receptor agonist — a pill, not an injection.

Status: Awaiting FDA approval. PDUFA date April 10, 2026. Expected at $149/month through LillyDirect and telehealth providers.

Why it matters: Orforglipron would be the first non-semaglutide oral GLP-1 for weight loss. Unlike oral Wegovy, which must be taken on an empty stomach 30 minutes before food, orforglipron can be taken at any time regardless of meals. At an announced $149/month, it would be the cheapest brand-name GLP-1 medication available — undercutting every injectable and matching the price of compounded semaglutide.

Clinical data (Phase 3):

  • 12.4% mean body weight loss at 36 mg over 72 weeks (ATTAIN-1 Phase 3 analysis)
  • No food-timing restrictions
  • 59% nausea rate during titration (most transient)
  • Discontinuation rates comparable to other GLP-1 medications (~7%)

What to expect post-approval:

  • Insurance coverage expected to roll out; Medicare eligibility through Bridge program ($50/mo copay, scheduled July 2026)
  • Telehealth prescribing expected to surge given the convenient oral format and competitive price
  • GI side effects anticipated to be consistent with trial data
  • Price announced at $149/month through LillyDirect

The trade-off: Less weight loss than injectables. The 12.4% mean loss is below tirzepatide (20.9%), semaglutide (14.9%), and oral Wegovy (16.6%). For patients whose primary goal is maximum weight loss, injectables remain more effective. But for patients who want a convenient, affordable oral option, orforglipron is expected to transform the market.

For a detailed breakdown, see our orforglipron complete guide.

2. Retatrutide (Eli Lilly) — Highest Efficacy Ever Recorded

What it is: A once-weekly injectable triple-agonist targeting GLP-1, GIP, and glucagon receptors simultaneously.

Why it matters: The glucagon receptor activation is what sets retatrutide apart from every other drug in the pipeline. It increases energy expenditure (the body burns more calories) and dramatically reduces liver fat — a two-pronged mechanism that has produced the highest weight loss numbers ever seen in a rigorous clinical trial.

Clinical data:

  • 28.7% mean body weight loss at 12 mg over 48 weeks (TRIUMPH-1 Phase 3) — the highest of any obesity drug trial
  • Over 70% of participants lost 20% or more of their body weight
  • 80-90% liver fat reduction in participants with elevated baseline liver fat
  • 16.8% weight loss in type 2 diabetes populations (TRANSCEND-T2D-1)
  • Weight loss curve had not yet plateaued at 48 weeks, suggesting potential for even greater losses with longer treatment

Where it stands: Seven Phase 3 trials under the TRIUMPH and TRANSCEND programs. TRIUMPH-1 and TRIUMPH-4 have reported primary results. Multiple other trials are enrolling or completing in 2026. An NDA is expected in 2027 if Phase 3 data continues to hold.

Timeline: Assuming successful completion of the Phase 3 program and standard FDA review, the earliest realistic approval is 2027-2028. This is an optimistic but reasonable estimate.

What we do not know: Long-term safety beyond 48 weeks, cardiovascular outcomes data, and real-world effectiveness. Phase 3 trials will provide more of this information, but some answers will only come after market launch.

For complete clinical data and comparisons, see our retatrutide complete guide.

3. Survodutide (Boehringer Ingelheim) — The NASH/Liver Fat Play

What it is: A once-weekly injectable dual agonist targeting GLP-1 and glucagon receptors.

Why it matters: Survodutide shares retatrutide's glucagon receptor activation — and the associated liver fat benefits — but without GIP. This makes it particularly interesting for NASH/MAFLD (metabolic-associated fatty liver disease), where glucagon-driven liver fat reduction could be transformative. Boehringer Ingelheim is pursuing obesity and liver disease indications in parallel.

Clinical data:

  • 18.7% mean body weight loss at the highest dose in Phase 2 (46 weeks)
  • Significant liver fat reduction consistent with glucagon receptor activation
  • GI side effects consistent with GLP-1 class, though nausea rates were somewhat higher than semaglutide in early data
  • Phase 2 data published in The Lancet

Where it stands: Phase 3 trials are running under the SYNCHRONIZE program. Primary results are expected late 2026. No NDA has been filed.

Timeline: If Phase 3 results are positive and submitted promptly, FDA approval could come in 2028 or later. This timeline depends heavily on Phase 3 results expected later this year.

How it compares: Survodutide's 18.7% weight loss in Phase 2 is less than retatrutide's 28.7% in Phase 3, but more than semaglutide's 14.9%. The absence of GIP agonism may explain the gap with retatrutide. However, Phase 2 and Phase 3 numbers are not directly comparable, and survodutide's Phase 3 data may tell a different story. Its potential advantage is in liver disease, where it may win a dedicated NASH indication before retatrutide does.

For full clinical data and NASH trial results, see our survodutide complete guide.

4. Amycretin / Zenagamtide (Novo Nordisk) — GLP-1 Meets Amylin

What it is: A dual GLP-1 and amylin receptor agonist being developed in both oral and injectable formulations.

Why it matters: Amylin is a hormone co-secreted with insulin that suppresses appetite through different brain pathways than GLP-1. Combining GLP-1 and amylin agonism in a single molecule — rather than two separate drugs (as CagriSema does) — could simplify dosing and potentially improve efficacy. This is Novo Nordisk's answer to retatrutide: a next-generation molecule designed to leapfrog its own semaglutide franchise.

Clinical data:

  • 22% mean body weight loss in Phase 1b/2 data (oral formulation)
  • Both oral and injectable formulations are in development
  • Side effect profile appears consistent with GLP-1 class in early data
  • Phase 1b/2 data is preliminary — sample sizes are small

Where it stands: Phase 3 trials initiated in Q1 2026. This is still early-stage for a Phase 3 program, meaning several years of trial enrollment, data collection, and regulatory review lie ahead.

Timeline: Phase 3 results are unlikely before 2028, with a potential FDA filing in 2028-2029 and approval in 2029-2030 at the earliest. This is a long-horizon drug.

The oral angle: If the oral formulation delivers on its Phase 1b/2 promise, amycretin could become the most effective oral weight loss medication — 22% weight loss in a pill would substantially exceed orforglipron (11.2%) and oral semaglutide (16.6%). But Phase 1b/2 data often does not replicate in larger Phase 3 trials, and the oral weight loss number should be treated as preliminary.

For detailed mechanism and trial data, see our amycretin complete guide.

5. CagriSema (Novo Nordisk) — Combination Approach

What it is: A fixed-dose combination of cagrilintide (a long-acting amylin analog) and semaglutide (the active ingredient in Wegovy and Ozempic) in a single weekly injection.

Why it matters: CagriSema takes two proven mechanisms — GLP-1 (semaglutide) and amylin (cagrilintide) — and combines them. The REDEFINE trial program showed that the combination produces substantially more weight loss than either drug alone. This is Novo Nordisk's most advanced next-generation product, with an NDA already filed.

Clinical data:

  • 23% mean body weight loss in the REDEFINE trials
  • Significantly more effective than semaglutide alone (~15%) or cagrilintide alone
  • Injectable, once weekly
  • Side effect profile similar to semaglutide, with some additional nausea attributed to the cagrilintide component

Where it stands: NDA filed with the FDA in December 2025. FDA review is underway. A PDUFA date has not been publicly announced as of this writing, but a decision is expected in 2026.

Timeline: If approved on a standard review timeline (10-12 months from filing), CagriSema could be available by late 2026 or early 2027. Priority review could accelerate this.

How it compares: CagriSema's 23% weight loss exceeds semaglutide (14.9%) and tirzepatide (20.9%), but falls short of retatrutide (28.7%). Its main advantage over retatrutide is timing — CagriSema is at least 1-2 years closer to market. For Novo Nordisk, CagriSema bridges the gap between its current semaglutide products and its longer-term amycretin pipeline.

For patient-focused information on CagriSema, see our CagriSema patient guide.

6. Aleniglipron (Structure Therapeutics) — The Next Oral Contender

What it is: A small-molecule oral GLP-1 receptor agonist — a different chemical approach than orforglipron but targeting the same receptor.

Why it matters: Aleniglipron has posted higher weight loss numbers than orforglipron in mid-stage trials, potentially positioning it as a more effective oral option. If Phase 3 confirms the Phase 2 data, aleniglipron could offer oral convenience with efficacy closer to injectable GLP-1s.

Clinical data:

  • 16.3% mean body weight loss at 180 mg in the ACCESS II Phase 2 trial
  • This exceeds orforglipron's 11.2% and is comparable to oral semaglutide (16.6%)
  • Side effect profile consistent with GLP-1 class
  • End-of-Phase 2 FDA meeting completed — the agency cleared the path to Phase 3

Where it stands: Phase 3 trials are expected to initiate in H2 2026. This puts aleniglipron approximately 2-3 years behind orforglipron in development.

Timeline: Phase 3 enrollment, data collection, and FDA review mean aleniglipron is unlikely to reach the market before 2028-2029 at the earliest.

The context: Aleniglipron's 16.3% weight loss in Phase 2 is promising, but Phase 2 numbers often do not fully replicate in larger Phase 3 trials. Orforglipron's own Phase 2 data suggested higher efficacy than its Phase 3 results ultimately confirmed. Whether aleniglipron maintains its advantage over orforglipron will only become clear once Phase 3 data is available.

7. Monthly Injectables — The Convenience Play

What they are: Several companies are developing once-monthly injectable formulations of GLP-1 or multi-agonist medications. Instead of weekly shots, patients would inject once every 30 days.

Why they matter: Adherence is one of the biggest challenges in GLP-1 therapy. Studies show that a substantial percentage of patients discontinue treatment within the first year, and injection frequency is a contributing factor. Monthly dosing could meaningfully improve long-term adherence by reducing the number of injections from 52 per year to 12.

Who is developing them:

  • Multiple pharmaceutical companies have monthly GLP-1 formulations in Phase 1 or Phase 2 trials
  • These include both reformulations of existing molecules and novel long-acting compounds
  • Specific company disclosures have been limited, with most programs in early clinical stages

Where they stand: Most monthly formulations are in Phase 1-2 development. None are close to FDA filing.

Timeline: The earliest monthly injectables are unlikely to reach the market before 2028-2029, and some programs may not progress beyond early trials.

The challenge: Maintaining consistent drug levels over 30 days is technically difficult. Too much drug early in the month could worsen side effects; too little late in the month could reduce efficacy. The pharmacokinetic challenge is the reason monthly formulations have taken longer to develop than the underlying drugs themselves.

What This Means for Patients

The pipeline creates several distinct scenarios depending on where you are in your treatment journey.

If you are not yet on a GLP-1 medication

You have more options approaching than at any point in this drug class's history. The most immediate change is orforglipron — if approved in April 2026, it offers a $149/month oral option that requires no injections and no food-timing restrictions. For patients who have been priced out of GLP-1 therapy or unwilling to use injections, this could be the entry point.

CagriSema's potential approval later in 2026 adds a more effective injectable option (23% weight loss) for those willing to use needles and who want maximum efficacy from what is currently available.

If you are already on semaglutide or tirzepatide

There is no reason to stop or switch based on pipeline drugs. Your current medication is FDA-approved, has extensive safety data, and is working. When new drugs reach the market, you can have a conversation with your prescriber about whether switching makes sense — but that conversation is months to years away for most of these medications.

The one near-term consideration: if you are on semaglutide and CagriSema is approved, it could offer a meaningful step up in efficacy (23% vs. 15% weight loss) within the same company's product line. Discuss with your prescriber when the time comes.

If you have plateaued on current medications

The pipeline is particularly relevant for you. Retatrutide's 28.7% weight loss and different mechanism of action (glucagon receptor activation) could offer a path forward for patients who have maximized their response to current GLP-1s. But retatrutide is 2+ years from availability. In the meantime, work with your prescriber on dose optimization, combination strategies, and lifestyle factors that may help break through a plateau.

If cost is your primary barrier

Orforglipron at $149/month could be the most significant development. That price point is 50-75% below current injectable GLP-1 self-pay costs. Additionally, as more drugs enter the market, competitive pressure is likely to drive prices down across the entire class — including for existing medications.

Should You Wait?

This is the question we hear most often. The honest answer depends on your situation.

In most cases, no — do not wait. Here is why:

  1. Effective medications exist today. Tirzepatide and semaglutide are proven, available, and have years of real-world data behind them. Orforglipron may be weeks from approval. Delaying treatment means forgoing real health benefits for a hypothetical future drug.

  2. Timelines are uncertain. FDA decisions can be delayed. Phase 3 trials can produce unexpected results. Manufacturing scale-up can cause shortages. Every estimated date in this guide could shift by months or years.

  3. Obesity is a progressive condition. The metabolic, cardiovascular, and joint damage associated with excess weight accumulates over time. Starting treatment now — even with a "less effective" current drug — prevents damage that a "more effective" future drug cannot reverse.

  4. You can switch later. Starting a GLP-1 now does not lock you in. If a better option becomes available, you can discuss switching with your prescriber. Many patients in the GLP-1 class have already transitioned from semaglutide to tirzepatide as new options emerged.

The one consideration: If you are interested in CagriSema's higher efficacy (23% weight loss) and it is close to an FDA decision, discussing the timing with your prescriber is reasonable. But this should be a specific, time-bound wait — not an open-ended delay. Orforglipron is already approved and available if you want an affordable oral option now.

FAQ

Which of these drugs will be available first?

Orforglipron is next in line — FDA approval is expected around April 2026 (PDUFA date April 10). If approved as anticipated, it will be available at $149/month. CagriSema has an FDA decision expected in late 2026. Everything else is at least 2 years away.

Will these new drugs be cheaper than current GLP-1s?

Orforglipron is priced at $149/month — substantially cheaper than injectable options. Beyond that, pricing for pipeline drugs is unknown. However, increased competition generally drives prices down. The entry of multiple new GLP-1s between 2026 and 2029 should create downward pressure on the entire class.

Is retatrutide really that much better than tirzepatide?

In clinical trials, yes — 28.7% vs. 20.9% mean weight loss. But retatrutide is not available, has no long-term safety data, no cardiovascular outcomes trial, and no real-world evidence. Tirzepatide is available now with all of those things. "Better" in a trial is not the same as "better for you right now."

What about compounded versions of these pipeline drugs?

There is no legitimate compounded version of any investigational drug. Retatrutide, survodutide, amycretin, and aleniglipron are patented investigational molecules that have never been commercially manufactured. Any product claiming to be a compounded version of these drugs is unregulated and potentially dangerous. We strongly advise against purchasing them.

Will my insurance cover these new drugs?

It depends on the drug, your insurance plan, and the approved indication. Historically, insurance coverage for obesity medications has been limited but is improving. Drugs approved for type 2 diabetes typically get better coverage than those approved only for obesity. Each new drug will go through its own coverage determination process with major insurers.

How do oral GLP-1 pills compare to injectables?

Currently, oral GLP-1s produce somewhat less weight loss than injectables. Orforglipron achieves 11.2% weight loss vs. 14.9-20.9% for injectable semaglutide and tirzepatide. Oral semaglutide (Wegovy pill) achieves 16.6%, and aleniglipron showed 16.3% in Phase 2. The gap is narrowing, and amycretin's early oral data (22%) suggests future oral options may match or approach injectable efficacy. The trade-off today is convenience vs. maximum efficacy.

What is the most effective weight loss drug in the pipeline?

Retatrutide, with 28.7% mean body weight loss in Phase 3 — the highest ever recorded in a rigorous obesity drug trial. However, it is also one of the furthest from market availability among the drugs covered here.

Should I enroll in a clinical trial for one of these drugs?

Clinical trial enrollment is a legitimate way to access investigational medications. Search ClinicalTrials.gov for the drug name to find active trial sites and eligibility criteria. Discuss with your physician whether participation is appropriate for your situation. Be aware that trials may include placebo arms, meaning you may not receive the active drug.

Are there safety concerns specific to these newer mechanisms?

Each new mechanism introduces theoretical considerations. Glucagon receptor activation (retatrutide, survodutide) could affect blood glucose — though trial data shows the GLP-1 component counteracts this. Amylin agonism (CagriSema, amycretin) can cause additional nausea beyond what GLP-1 alone produces. Small-molecule oral GLP-1s (orforglipron, aleniglipron) are chemically different from peptide-based drugs and may have different off-target effects. None of these have raised red flags in trials so far, but larger and longer studies are needed.

When will this guide be updated?

We update this guide as new clinical data is published, FDA decisions are announced, or timelines change materially. Check the "last updated" date at the top of the page. For breaking developments, follow our coverage of individual drugs through the linked guides above.

This guide is for informational purposes only and does not constitute medical advice. Orforglipron is awaiting FDA approval (PDUFA April 10, 2026); the remaining medications discussed are investigational and have not been approved by the FDA. All clinical data is based on published trial results, company disclosures, and regulatory filings, which are subject to change. Timelines are estimates and may shift. Consult with a qualified healthcare provider before making any treatment decisions. Last updated April 2026.

Related Comparisons

Amazon Clinic vs Ro Health for GLP-1 Weight Loss: Big Tech vs Dedicated Program

Amazon Clinic vs Ro Health for GLP-1: retail giant pharmacy access vs dedicated weight loss program. Pricing, clinical depth, and medication access compared. April 2026.

Eden Health vs Ro for GLP-1: 2026 Comparison

Eden Health vs Ro compared side-by-side — flat-rate compounded pricing vs brand-name medications, and which GLP-1 provider fits your situation in 2026.

eMed vs Ro for GLP-1 Weight Loss: 2026 Comparison

eMed vs Ro compared side-by-side — smart scale, video consultations, and adherence tech vs Ro's streamlined brand-name GLP-1 approach. Pricing, clinical model, and who each fits.

More Guides

Insurance & Cost

Does Aetna Cover GLP-1 Medications? 2026 Coverage Guide

Patient Guides

Aleniglipron: Structure Therapeutics' Oral GLP-1 — What Patients Need to Know

Complete guide to aleniglipron, Structure Therapeutics' investigational oral GLP-1 showing 16.3% placebo-adjusted weight loss at 44 weeks in Phase 2 ACCESS II — the highest weight loss reported for any oral GLP-1 to date. Only 3.7% discontinuation rate. Phase 3 expected H2 2026, with earliest FDA approval in 2028 or later.

Patient Guides

Amycretin (Zenagamtide): Novo Nordisk's Next-Gen GLP-1/Amylin Agonist

Complete guide to amycretin (zenagamtide) — Novo Nordisk's GLP-1/amylin dual agonist with 22% weight loss in early trials. Phase 3 starting 2026, oral and injectable paths.

Patient Guides

AOD-9604 for Weight Loss: Telehealth Providers Guide 2026

Patient Guides

Best GLP-1 Medication 2026: Every Approved Option Ranked by Use Case

The GLP-1 medication landscape changed substantially in 2026 with two new approvals — Wegovy HD (April 2026) and Oral Wegovy — with orforglipron awaiting FDA approval (PDUFA April 10, 2026) and a Medicare bridge program scheduled for July 2026. This guide ranks every approved GLP-1 by use case, walks through the decision framework, and covers what is worth watching in the pipeline.

Patient Guides

Which GLP-1 Has the Fewest Side Effects? A Medication-by-Medication Comparison

Which GLP-1 medication has the least side effects? Data-driven comparison of semaglutide, tirzepatide, liraglutide, dulaglutide, and orforglipron tolerability profiles.

Patient Guides

Best GLP-1 Options After Foundayo Approval: Oral vs Injectable 2026

Medications

Best GLP-1 Pill Options in 2026: Oral Wegovy, Orforglipron & More

The GLP-1 pill category is expanding fast. Here's every oral GLP-1 option available in 2026 — from oral Wegovy to orforglipron's delayed timeline — with real pricing and where to get them.

Patient Guides

Best Oral GLP-1 Options 2026: Foundayo vs Rybelsus Complete Comparison

Insurance & Cost

Best GLP-1 Under $200 Per Month: 2026 Budget Guide

Effective GLP-1 medications are available under $200/month in 2026. Oral Wegovy at $199/month is the best FDA-approved option — 15.1% mean weight loss in a daily pill with no injection. Orforglipron received a Complete Response Letter from the FDA on April 10, 2026 and is not yet available. Compounded semaglutide remains accessible at lower prices but with increasing regulatory risk. This guide covers every option, access strategies, and how to choose.

Providers

Best GLP-1 Weight Loss Programs 2026: Every Major Provider Ranked

Every major GLP-1 weight loss program ranked — real pricing, clinical models, and honest assessments. No provider paid for placement.

Patient Guides

Best Growth Hormone Peptide Providers Online: 2026 Independent Comparison

Patient Guides

Best Online HRT 2026: Telehealth Menopause Treatment Platforms Compared

Independent comparison of the best online HRT and menopause telehealth platforms — Winona, Alloy, Midi Health — with pricing, insurance options, and clinical credentials.

Providers

Best Online TRT Clinics 2026: Telehealth Testosterone Replacement Compared

Independent comparison of the top online TRT clinics — pricing, protocols, enclomiphene vs injectable, and which telehealth providers are worth it.

Medications

Best Oral GLP-1 Options in 2026: Every Pill Compared

The oral GLP-1 market is transforming in 2026 with oral Wegovy already launched and orforglipron's FDA decision expected April 2026 at $149/month. Here is every oral GLP-1 compared on price, efficacy, convenience, and access.

Patient Guides

Best Telehealth Providers for Tirzepatide 2026: Ranked by Price and Care

The best telehealth providers for tirzepatide in 2026, ranked by price, protocol, and care quality. From $278/month compounded to brand Zepbound via insurance. No provider paid for placement.

Providers

Best Weight Loss Injection 2026: Wegovy HD, Zepbound, and Every Option Compared

Every FDA-approved weight loss injection compared for 2026. Wegovy HD 7.2mg, Zepbound, Wegovy 2.4mg — efficacy, pricing, side effects, and who each is best for. Plus oral options (Oral Wegovy, orforglipron pending FDA approval).

Patient Guides

Best Weight Loss Medication 2026: Every FDA-Approved Option Ranked

Every FDA-approved weight loss medication compared in one place — GLP-1s (Wegovy, Zepbound, orforglipron), non-GLP-1 pills (Contrave, Qsymia, phentermine, Xenical), and off-label options (Ozempic, metformin). Efficacy, pricing, side effects, insurance, and how to choose.

Insurance & Cost

Does Blue Cross Blue Shield Cover GLP-1 Medications? 2026 Guide

Patient Guides

Best BPC-157 Telehealth Providers 2026: Complete Guide

Patient Guides

BPC-157 vs TB-500: Which Injury Recovery Peptide Is Right for You?

Medications

CagriSema Dosing Guide: Titration Schedule, Dose Steps & What to Expect

Complete CagriSema dosing and titration guide based on REDEFINE trial protocols. Cagrilintide + semaglutide dose steps, injection schedule, and how CagriSema dosing compares to Wegovy and Zepbound.

Medications

CagriSema Launch Day Patient Guide: What to Do Now That It's Here

CagriSema — the cagrilintide/semaglutide combination — has received FDA approval. This launch day guide covers everything patients need to know: how to get it, expected pricing, insurance strategies, how it compares to existing options, and a step-by-step action checklist.

Patient Guides

CagriSema: The Semaglutide + Cagrilintide Combination — Patient Guide

Complete guide to CagriSema — Novo Nordisk's cagrilintide + semaglutide combination with 23% weight loss. NDA filed December 2025, under FDA review with no PDUFA date disclosed. Full status update.

Patient Guides

CagriSema FDA Decision Guide: What to Expect and How to Prepare

CagriSema NDA filed December 2025 — under FDA review with no PDUFA date disclosed. What the uncertainty means, approval scenarios, and what patients should do now.

Patient Guides

CagriSema: What Patients Need to Know While the FDA Decision Drags On

CagriSema's NDA has been under FDA review for 18 months with no decision. What patients should know about the delay, available alternatives like orforglipron and Wegovy HD, and how to plan around uncertainty.

Medications

CagriSema Side Effects: What Clinical Trials Show About Safety and Tolerability

Comprehensive guide to CagriSema side effects based on REDEFINE Phase 3 clinical trial data. Covers GI effects, injection site reactions, serious risks, comparisons to semaglutide and tirzepatide, management strategies, and what remains unknown pre-approval.

Insurance & Cost

Cheapest GLP-1 Without Insurance in 2026: Every Option Ranked by Price

You do not need insurance to access a GLP-1 in 2026. The cheapest options start at $129/month for compounded semaglutide, $149/month for orforglipron, and $199/month for oral Wegovy. Here is everything ranked and explained.

Insurance & Cost

Cheapest GLP-1 Without Insurance in 2026: Every Option Ranked by Price

You do not need insurance to access a GLP-1 in 2026. The cheapest options start at $129/month for compounded semaglutide, $149/month for orforglipron, and $199/month for oral Wegovy. Here is everything ranked and explained.

Patient Guides

CJC-1295 vs Ipamorelin: Complete Telehealth Comparison Guide 2026

Insurance & Cost

CMS BALANCE Model Explained: Medicaid Obesity Care for 2026 and Beyond

Complete guide to the CMS BALANCE Model — the new Medicaid obesity care program launching in 2026. Learn which states are participating, what's covered, and how to access GLP-1 medications through Medicaid.

Insurance & Cost

Medicare GLP-1 Bridge Program: Implementation FAQ for Patients

Practical FAQ for the Medicare Part D GLP-1 bridge program launching July 2026 — how to enroll, which pharmacies participate, copay details, and what to expect.

Insurance & Cost

Compounded GLP-1 Shutdown Timeline: From Shortage to Enforcement (2023–2026)

From the 2023 shortage that opened the door to compounding, through the ongoing 2026 enforcement campaign — warning letters and pharmacy supply declines — this is the complete timeline of the compounded GLP-1 market. Updated April 2026.

Patient Guides

Is Compounded HRT Safe? What Patients Need to Know in 2026

Side Effects

Is Compounded Semaglutide Legal and Safe in 2026?

Is compounded semaglutide still legal? We break down the current FDA rules, 30 new warning letters, SAFE Drugs Act, Hims exiting compounded, and what this means for your prescription.

Insurance & Cost

Compounded Tirzepatide 2026: What's Happening and What Patients Should Do

Compounded tirzepatide is under active FDA enforcement as of April 2026 — supply is declining but not yet at zero. The 503B enforcement discretion ended over a year ago (March 2025); the FDA has now issued 50+ warning letters including a 30-letter batch in April 2026. Here's what patients need to know and what to do.

Patient Guides

Contrave Guide 2026: How It Works, Weight Loss Results & How It Compares to GLP-1s

Complete guide to Contrave (bupropion/naltrexone) for weight loss — how it works, clinical trial results (5-8% weight loss), side effects, pricing ($50-100/month generic), and honest comparison to GLP-1 medications like Wegovy and Zepbound.

Insurance & Cost

Does Insurance Cover GLP-1 Medications? Complete 2026 Guide

GLP-1 insurance coverage depends on your plan type, your diagnosis, and which medication you need. This guide breaks down coverage by plan type — commercial, Medicare, Medicaid, ACA, and military — so you can find your specific situation fast.

Insurance & Cost

Does Insurance Cover Semaglutide? 2026 Coverage Guide

Insurance & Cost

Does Medicare Cover Ozempic? What You Need to Know in 2026

Does Medicare cover Ozempic in 2026? Yes for diabetes, no for weight loss. Learn about Part D coverage rules, costs, prior authorization, and cheaper alternatives.

Insurance & Cost

Does Medicare Cover Wegovy? Complete 2026 Coverage Guide

Medicare Part D is expanding Wegovy coverage for weight loss via the Bridge program (scheduled July 1, 2026). Here's what's expected, what you'll pay, how to qualify, and how to navigate prior authorization.

Patient Guides

DSIP (Delta Sleep-Inducing Peptide) Telehealth Providers Guide 2026

Medications

Enclomiphene vs TRT: What Is the Difference and Which Is Right for You?

A clinical comparison of enclomiphene and testosterone replacement therapy — how they work, who each is best for, fertility implications, and current research.

Patient Guides

Epitalon Longevity Peptide: Telehealth Providers Guide 2026

Patient Guides

FDA Enforcement Actions: What Happened After April 2 — Company Responses, Market Impact, and Patient Guidance

Side Effects

FDA Enforcement Actions Against Telehealth Providers: The Complete Tracker

55+ FDA warning letters in September 2025. 30 more in February 2026. DOJ referrals. Criminal guilty pleas. The FDA's enforcement wave against telehealth GLP-1 providers is the largest in the industry's history. Here's the full record.

Insurance & Cost

FDA GLP-1 Enforcement Actions Tracker: April 2026 Warning Letters and What Comes Next

On March 12, 2026, the FDA issued 30 warning letters to compounding pharmacies and telehealth companies prescribing GLP-1 medications — the largest single-day enforcement action in the industry's history. Companies had until April 2-3 to respond. This tracker documents every action, explains what comes next, and tells you what to do if your provider is on the list.

Side Effects

FDA GLP-1 Warning Letters Tracker: Compounding Pharmacies Under Scrutiny

Live tracker of FDA warning letters, enforcement actions, and regulatory updates targeting GLP-1 compounding pharmacies — what patients need to know about medication safety.

Patient Guides

FDA requests additional safety data for Eli Lilly’s GLP-1 weight-loss pill

Insurance & Cost

FDA GLP-1 Telehealth Crackdown: What Patients Need to Know

The FDA issued 30+ warning letters to telehealth firms prescribing compounded GLP-1s. Here's what patients need to know, how to check if your provider was flagged, and what your safe alternatives are.

Patient Guides

Foundayo Provider Availability Tracker: Where to Get Orforglipron Online 2026

Insurance & Cost

Generic Liraglutide (Saxenda Generic): The Budget GLP-1 Nobody's Talking About

Generic liraglutide from Teva is the first generic GLP-1 for weight loss. At ~$230/month, is it a viable budget alternative to semaglutide and orforglipron? Complete pricing and comparison guide.

Insurance & Cost

Generic Ozempic & Semaglutide: Timeline, Patents, and What to Expect

When will generic semaglutide (Ozempic) be available in the US? Patent landscape, international generics at $3/month, biosimilar timeline, and what you can do now to save.

Patient Guides

GHK-Cu Copper Peptide: Telehealth & Skincare Providers Guide 2026

Patient Guides

GLP-1 Cost Calculator

Patient Guides

GLP-1 Insurance Coverage Guide 2026: Complete Provider & Plan Analysis

Patient Guides

GLP-1 Medications: How They Work for Weight Loss

Patient Guides

GLP-1 Side Effects Management Guide: Evidence-Based Solutions for 5 Common Issues

Patient Guides

Telehealth vs In-Person: Which Is Better for GLP-1?

Results & Benefits

GLP-1 in 2026: What to Watch

What's shaping the GLP-1 landscape in 2026 — orforglipron FDA decision, Wegovy HD, Medicare Bridge program, compounding crackdown, CagriSema pending, and what it all means for patients.

Results & Benefits

GLP-1 Medications and Addiction: What the Evidence Really Shows

Does semaglutide reduce addiction and cravings? A deep review of the Lancet Psychiatry and JAMA Psychiatry data, the brain reward mechanism, what's proven vs. anecdotal, and what GLP-1s cannot replace.

Results & Benefits

GLP-1 Adherence & Retention: Why Most Patients Quit and How to Stay on Track

The real GLP-1 adherence data — persistence rates from 33% to 61%, why patients quit, what providers do differently, and evidence-based strategies to stay on your medication.

Side Effects

GLP-1 and Acid Reflux: Managing GERD on Semaglutide or Tirzepatide

Patient Guides

GLP-1 Medications and Alcohol: What You Need to Know

Alcohol and GLP-1 medications: what the clinical data shows about interactions, how oral GLP-1s like orforglipron may differ from injectables, the surprising 'curbed drinking' effect many patients experience, real safety risks to know about, and practical guidance for patients who drink.

Patient Guides

GLP-1 and Birth Control: Interaction Risks, Safe Options, and Provider Guidance 2026

Results & Benefits

GLP-1 and Exercise: Performance, Muscle Preservation & Workout Guide

How GLP-1 medications affect exercise performance — muscle loss risk, protein needs, resistance training protocols, cardio adjustments, and tips for staying fit on semaglutide or tirzepatide.

Patient Guides

GLP-1 and Gallbladder Risk: What Patients Need to Know

Do GLP-1 medications increase gallbladder disease risk? JAMA meta-analysis data on gallstones, cholecystitis, dose-dependent risk, and how to protect yourself.

Patient Guides

GLP-1 and Hormone Therapy: Safety, Interactions, and What to Monitor

Results & Benefits

GLP-1 and Joint Pain: How Weight Loss Medications Affect Arthritis and Joint Health

Can GLP-1 medications like Ozempic, Wegovy, and Zepbound help with joint pain and arthritis? Research on weight-mediated relief, direct anti-inflammatory effects, and what patients should know.

Results & Benefits

GLP-1 Medications and Mental Health: What the Evidence Shows

GLP-1 medications and mental health review — Lancet Psychiatry 42% risk reduction data, suicidal ideation concerns, and what patients need to know.

Patient Guides

GLP-1 and Sleep: How Weight Loss Medications Affect Your Rest

How do GLP-1 medications like Ozempic, Wegovy, and Zepbound affect sleep? Research on insomnia, sleep apnea improvement, and practical tips for better rest.

Insurance & Cost

GLP-1 Price Changes 2026: Complete Pricing Timeline

2026 is shaping up as the most volatile year for GLP-1 pricing ever — Novo's list price cuts, oral Wegovy's tiered pricing, orforglipron's April 10 PDUFA date, GoodRx's intro price expiring April 15. Here's every change and what it means for your wallet.

Patient Guides

GLP-1 Body Changes: Ozempic Butt, Loose Skin, and What to Expect

What is Ozempic butt? How GLP-1 medications change your body — loose skin, fat redistribution, muscle loss appearance, and evidence-based strategies to manage body composition changes.

Patient Guides

GLP-1 and Colonoscopy Prep: What Your Gastroenterologist Wants You to Know

Should you stop Ozempic, Wegovy, or Mounjaro before a colonoscopy? Current AGA guidelines, bowel prep tips for GLP-1 users, and what to tell your GI doctor.

Patient Guides

GLP-1 Combination Therapy: Evidence-Based Guide to Multi-Drug Protocols

Insurance & Cost

GLP-1 Compounding Alternatives: What to Do After the FDA Crackdown

The FDA has shut down dozens of compounding pharmacies selling semaglutide and tirzepatide. If you were on compounded GLP-1s, here are your actual options — with real pricing, provider comparisons, and savings programs.

Side Effects

GLP-1 Compounding Crackdown Q4 2026: What Patients Need to Do Now

The FDA's GLP-1 compounding enforcement is escalating in Q4 2026 — DOJ referrals, pharmacy shutdowns, and supply disruptions. What patients on compounded medications need to do right now.

Side Effects

GLP-1 Constipation: Why It Happens and How to Manage It

Constipation affects 12-24% of GLP-1 users. Why semaglutide and tirzepatide cause constipation, evidence-based management strategies, and when to contact your doctor.

Patient Guides

GLP-1 Cost Guide: Every Price, Every Drug, Every Provider

GLP-1 medications range from $129/month (compounded telehealth) to $1,349/month (brand Wegovy without insurance). This guide covers every drug, every provider, and every savings option.

Patient Guides

GLP-1 and Dementia: What the Research Actually Shows

What does the research actually show about GLP-1 medications and dementia? Review of the Cleveland Clinic study, EVOKE trial, mechanisms, and honest limits of current evidence.

Patient Guides

GLP-1 and Depression: What the Evidence Actually Shows in 2026

Evidence-based review of GLP-1 medications and depression/anxiety — what major studies found, what the mechanisms might be, and what patients should know. Updated April 2026.

Patient Guides

GLP-1 Medications and Depression / Anxiety: What the 2026 Evidence Actually Shows

Does Ozempic help depression? Does semaglutide worsen anxiety? The 2026 Lancet Psychiatry cohort of 95,490 patients, the FDA suicidal ideation investigation, and evidence-based guidance for patients.

Results & Benefits

GLP-1 Medications and Diabetes Prevention: What the Research Shows

Approximately 96 million American adults have prediabetes, and up to 70% of them will eventually develop type 2 diabetes. GLP-1 medications are showing strong evidence for preventing that progression — but the picture is more nuanced than headlines suggest. Here is what the clinical data actually shows, who might benefit most, and how to access these medications for prevention.

Side Effects

GLP-1 Diarrhea: Why It Happens and How to Manage It

Diarrhea affects 15-30% of GLP-1 users. Why semaglutide and tirzepatide cause diarrhea, evidence-based management strategies, and when to seek medical attention.

Patient Guides

GLP-1 Dosing & Titration Schedules Explained

Complete GLP-1 dosing and titration schedules for Wegovy, Ozempic, Zepbound, Mounjaro, and oral Wegovy. Understand each dose step, what to expect, and when to adjust.

Patient Guides

GLP-1 Telehealth Outcomes: What the Real-World Data Actually Shows

Analysis of real-world GLP-1 outcomes data from DTC telehealth platforms — actual weight loss results, adherence rates, discontinuation patterns, and how telehealth results compare to clinical trials.

Patient Guides

GLP-1 Effectiveness Across Demographics: Does It Work for People Like You?

One of the most common questions about GLP-1 medications: will it work for someone like me? A 2026 Johns Hopkins study of nearly 100,000 patients shows GLP-1s are comparably effective across age, race, and starting weight — but important nuances exist.

Insurance & Cost

Does Your Employer Cover GLP-1 Medications? 2026 Guide

43% of large employers now cover GLP-1s for weight loss. Find out if your employer covers Wegovy, Zepbound, or orforglipron — plus how to check, ADA implications, and what to do if denied.

Patient Guides

GLP-1 Medications and Exercise: Performance, Muscle, and Workout Tips

How do GLP-1 medications affect exercise performance? What gym-goers and athletes should know about working out on semaglutide or tirzepatide — muscle preservation, energy, and training adjustments.

Results & Benefits

GLP-1 Food Aversion: Why Food Tastes Different and What to Do About It

The GLP-1 food aversion effect explained — why food tastes different, the 'food noise' phenomenon, how to maintain nutrition when appetite disappears, and when to worry.

Patient Guides

GLP-1 for Men: Weight Loss Results, Testosterone Effects, and Best Options in 2026

GLP-1 medications like semaglutide and tirzepatide are highly effective for men's weight loss, typically producing 15-20% body weight reduction. This guide covers testosterone interactions, muscle preservation strategies, and male-friendly provider options.

Patient Guides

GLP-1 Medications for PCOS: What the Research Shows

GLP-1 prescriptions for PCOS patients surged 637% from 2020-2025. Here's what the evidence actually shows about semaglutide and tirzepatide for polycystic ovary syndrome.

Patient Guides

GLP-1 for Seniors: A Complete Guide to Weight Loss Medications After 65

GLP-1 medications can be effective for adults over 65, but seniors face unique risks including muscle loss, drug interactions, and dehydration. Here's what to know about safety, Medicare coverage, and finding the right provider.

Patient Guides

Can You Get a GLP-1 Prescription Without Diabetes?

Yes — Wegovy and Zepbound are FDA-approved for weight loss without diabetes. Here's who qualifies, how to get a prescription, and what insurers will and won't cover.

Results & Benefits

GLP-1 Friendly Diet: What to Eat on Semaglutide, Tirzepatide & Other GLP-1s

Complete guide to eating well on GLP-1 medications, emphasizing a protein-first strategy of 1.2-1.6g per kg body weight daily to preserve lean muscle mass. Covers best foods by category, meal planning, the GLP-1 restaurant menu trend, and supplement considerations.

Side Effects

GLP-1 Gastroparesis Risk: What Patients Need to Know About Stomach Paralysis

Do Ozempic, Wegovy, or other GLP-1 medications cause gastroparesis? JAMA data on 3.67x risk, prevention strategies, warning signs, and what to do if you're affected.

Patient Guides

GLP-1 Medications and Hair Loss: What Patients Should Know

Can GLP-1 medications like semaglutide and tirzepatide cause hair loss? What the clinical data shows, why it happens, and what you can do about it.

Results & Benefits

GLP-1 Heart Benefits Beyond Weight Loss: What the SELECT Trial Tells Us

The SELECT trial showed GLP-1 medications reduce heart attack and stroke risk by 20% — and the benefits appear independent of weight loss. Here's what the cardiovascular data means for patients.

Results & Benefits

Do GLP-1 Heart Benefits Fade After Stopping? What Patients Need to Know

Emerging data suggests the cardiovascular benefits of GLP-1 medications may diminish after stopping. Here's what patients should understand about long-term treatment decisions.

Results & Benefits

GLP-1 Heart Benefits: What the SELECT Trial and New Research Show

Deep dive into GLP-1 cardiovascular benefits — SELECT trial 20% MACE reduction, HFpEF indication for semaglutide, and what heart protection means for weight loss patients.

Patient Guides

GLP-1 Hidden Costs Exposed: True Total Cost Analysis by Provider

Patient Guides

GLP-1 Medications During the Holidays: A Practical Guide

The holidays bring unique challenges for patients on GLP-1 medications — from navigating family dinners with a reduced appetite to traveling with injectables and handling the inevitable 'have you lost weight?' conversations. This guide covers practical strategies for every scenario.

Patient Guides

GLP-1 Injection Technique Guide: Where to Inject, How to Rotate, and Tips for Less Pain

Step-by-step GLP-1 injection technique guide covering where to inject, site rotation, storage, pain management, and common mistakes. Covers Wegovy, Ozempic, Zepbound, and orforglipron.

Patient Guides

GLP-1 Insurance Coverage Guide: How to Get Your Medication Covered

GLP-1 insurance coverage depends on your diagnosis, plan, and employer. This guide explains what's covered, what isn't, how prior authorization works, and how to fight a denial.

Results & Benefits

GLP-1 and Kidney Protection: What the FLOW Trial Means for Patients

The FLOW trial showed semaglutide reduced kidney disease progression by 24% — so significant the trial stopped early. What this means for patients with or at risk for kidney disease.

Patient Guides

GLP-1 Medications and Knee Replacement: Pre-Surgery Weight Loss, Recovery, and What to Know

Should you use GLP-1 medications before knee replacement? Evidence on pre-surgical weight loss, when to stop Ozempic or Zepbound before surgery, recovery nutrition, and what orthopedic surgeons recommend.

Results & Benefits

GLP-1 and Liver Disease: How Semaglutide and Tirzepatide Are Treating NASH/MASH

How GLP-1 medications are transforming liver disease treatment — ESSENCE trial shows 62.9% MASH resolution with semaglutide, SYNERGY-NASH tirzepatide data, and what this means for patients.

Patient Guides

GLP-1 Long-Term Safety: What 5+ Years of Data Actually Shows

Is it safe to take GLP-1 medications long-term? Review of 5+ year safety data for semaglutide, tirzepatide, and liraglutide — what research shows and what's still unknown.

Patient Guides

GLP-1 Maintenance After Plateau: Long-Term Strategies That Actually Work

Once you've hit a GLP-1 weight loss plateau, the question shifts from 'how do I lose more?' to 'how do I keep what I've lost?' This guide covers the evidence on long-term GLP-1 maintenance — including dose adjustment strategies, the orforglipron oral switch option, combination approaches, and what clinical data says about staying at your new weight.

Results & Benefits

GLP-1 Maintenance Guide: How to Keep the Weight Off Long-Term

Complete guide to maintaining weight loss on GLP-1 medications — maintenance dosing strategies, lifestyle habits that stick, when to reduce doses, and preventing the regain trap.

Patient Guides

GLP-1 Medication Comparison Chart 2026: Every Weight Loss Drug Compared

Master comparison chart of every GLP-1 weight loss medication in 2026 — semaglutide, tirzepatide, orforglipron, retatrutide, and CagriSema compared by efficacy, pricing, side effects, insurance coverage, and availability to help you choose the right option.

Patient Guides

GLP-1 and Muscle Loss: What Patients Need to Know

Do GLP-1 medications like Wegovy and Zepbound cause muscle loss? What the research actually shows, how much lean mass is lost, and evidence-based strategies to preserve muscle.

Results & Benefits

GLP-1 and Muscle Loss: What the Research Actually Shows

The truth about GLP-1 muscle loss — STEP trial data shows 25-40% of weight lost is lean mass. What that means, how to minimize it, and why the headline stats need context.

Side Effects

GLP-1 Nausea Management Guide: How to Handle the Most Common Side Effect

Nausea affects up to 44% of patients starting GLP-1 therapy. This guide covers why it happens, evidence-based strategies to reduce it, and when to contact your provider.

Patient Guides

Starting a GLP-1 Medication in January: A Realistic New Year's Resolution Guide

January is the most popular month to start GLP-1 medications — insurance deductibles reset, motivation is high, and provider schedules open up. This guide covers realistic timelines, medication choices, cost strategies, and the mistakes that derail most January starters before spring.

Patient Guides

GLP-1 Medications Before Surgery: The SPAQI Perioperative Consensus Guide

Evidence-based guidance on managing GLP-1 medications around surgery. Covers SPAQI multidisciplinary consensus, medication-specific hold times, aspiration risk, and post-surgical restart protocols.

Patient Guides

GLP-1 Medications and Pregnancy: What You Need to Know

Are GLP-1 medications safe during pregnancy? What to know about semaglutide, tirzepatide, orforglipron, and fertility — including when to stop, washout periods, and the 'Ozempic baby' phenomenon.

Patient Guides

GLP-1 Price Transparency Index 2026: Which Providers Publish Real Pricing?

Providers

GLP-1 Pricing Breakdown: What Each Provider Actually Charges in 2026

What does GLP-1 medication actually cost? We broke down real pricing from 10 telehealth providers — monthly costs, hidden fees, and what you're paying for.

Insurance & Cost

GLP-1 Prior Authorization Guide: How to Get Semaglutide & Tirzepatide Covered by Insurance

Insurance prior authorization is the #1 barrier to GLP-1 access. This guide walks you through every step — from eligibility criteria to appeal letters.

Patient Guides

Best Customer Service GLP-1 Provider 2026: Response Times & Support Quality Compared

Patient Guides

Fastest GLP-1 Provider Onboarding: Time to First Dose Comparison 2026

Patient Guides

GLP-1 Provider Safety Scorecard: FDA Compliance Analysis 2026

Patient Guides

GLP-1 Side Effects: What to Expect by Medication

Side effects of every major GLP-1 medication compared — Wegovy, Zepbound, Ozempic, Mounjaro, oral Wegovy. What's common, what's rare, when to call your doctor.

Patient Guides

GLP-1 Side Effects: What to Expect in the First Month

A week-by-week breakdown of GLP-1 side effects in the first month. What's normal at weeks 1, 2, 3, and 4 — and when to call your doctor.

Patient Guides

GLP-1 Side Effects Guide: What to Expect and How to Manage Them

GLP-1 side effects are common and manageable for most patients. This guide covers what to expect, how to reduce nausea, when to call your doctor, and how side effects compare across medications.

Patient Guides

GLP-1 Medications for Sleep Apnea: SURMOUNT-OSA Data and Treatment Guide

How GLP-1 medications treat obstructive sleep apnea. SURMOUNT-OSA trial data showing 55-63% AHI reduction with tirzepatide, Zepbound OSA approval, CPAP comparison, and practical treatment guidance.

Patient Guides

GLP-1 Telehealth Access by State 2026: Provider Availability and Medicaid Coverage for Every State

Patient Guides

Real-World GLP-1 Weight Loss Results from Telehealth: What to Actually Expect

Clinical trials report GLP-1 weight loss of 15-22%. But what happens in the real world, through telehealth? New data shows 18.53% weight loss at 18 months — closer to trial results than anyone expected. Here's why, and what it means for your decision.

Side Effects

GLP-1 Telehealth Prescriber Networks: Who Is Actually Prescribing Your Medication?

Behind the branded app and the slick enrollment flow, your GLP-1 prescription comes from a physician affiliated with a medical group you have probably never heard of. A handful of these groups power a surprisingly large share of the market — and many appeared in the FDA's April 2026 warning letter sweep.

Insurance & Cost

GLP-1 Telehealth Pricing Report Q2 2026: The State of the Market

Original pricing report tracking GLP-1 medication costs across 30+ telehealth providers in Q2 2026, covering compounded semaglutide price compression, Medicare coverage impact, oral Wegovy pricing shifts, and provider consolidation trends.

Providers

GLP-1 Telehealth Provider Comparison 2026: Every Provider, Side by Side

Every major GLP-1 telehealth provider compared in one place — real pricing, consultation types, lab testing, peptide selection, and what actual patients say.

Patient Guides

GLP-1 Telehealth Red Flags: What to Avoid When Choosing a Provider

Not all GLP-1 telehealth providers meet the same safety standards. This guide covers the warning signs to watch for, what good providers do differently, and a safety checklist before you enroll.

Side Effects

GLP-1 Telehealth Safety: What Your Doctor Wants You to Know

67% of PCPs are concerned about telehealth GLP-1 prescribing. Here's what primary care doctors worry about — and what patients should watch for to stay safe.

Results & Benefits

GLP-1 Telehealth in 2026: What Changed and What's Next

How the GLP-1 telehealth market transformed in 2026 — FDA enforcement, Hims' compounding exit, orforglipron approval, Medicare Bridge, and what it means for patients.

Patient Guides

GLP-1 and Thyroid Cancer: What Patients Need to Know

Understanding the thyroid cancer warning on GLP-1 medications — what the research shows, who should avoid these drugs, and what to monitor.

Patient Guides

Traveling with GLP-1 Medications: Complete Guide

Everything you need to travel confidently with GLP-1 medications: TSA rules for injectable pens, temperature storage requirements, dose timing across time zones, international travel considerations, emergency refill options, and a complete packing checklist.

Results & Benefits

GLP-1 for Weight Loss AND Type 2 Diabetes: The Dual-Indication Advantage

If you have both obesity and type 2 diabetes, GLP-1 medications can treat both conditions simultaneously — and the diagnosis you use to prescribe under can dramatically affect your insurance coverage, out-of-pocket cost, and medication options.

Patient Guides

GLP-1 Weight Loss Plateau: Why It Happens and What to Do About It

Weight loss plateaus on GLP-1 medications are real, common, and well-documented — not a sign the medication has stopped working. This guide explains the physiology behind GLP-1 plateaus, when they typically occur, what clinical trials show about expected weight loss ceilings, and your evidence-based options for moving forward.

Patient Guides

GLP-1 and Weight Regain: What Happens When You Stop and How to Prevent It

The hardest part of GLP-1 treatment isn't losing weight — it's keeping it off. Clinical trials show most patients regain 60-70% of lost weight within a year of stopping. Here's what the research says about preventing regain and building a sustainable long-term plan.

Insurance & Cost

How to Get GLP-1 Medications Without a Monthly Subscription

Don't want a monthly subscription for GLP-1 medications? Here are all the pay-per-visit and non-subscription options — Walgreens $49 visits, CVS MinuteClinic, your PCP, and more.

Patient Guides

Healing Peptides Beyond GLP-1: Complete Provider Options Guide

Providers

Hims GLP-1 Guide 2026: Everything About Their Weight Loss Program

Everything about Hims' GLP-1 weight loss program in 2026 — branded Wegovy (including HD 7.2mg), oral Wegovy, Zepbound, confirmed pricing, insurance billing, and the completed compounding exit.

Side Effects

Hims Semaglutide Compounded 2026: The Novo Nordisk Settlement Explained

Hims went from launching a $49/day compounded semaglutide pill to settling a Novo Nordisk lawsuit — all in 32 days. Here's the complete story, what it costs patients, and what the market looks like now.

Providers

Hims Wegovy: Everything About the Novo Nordisk Deal, Pricing & Transition

Complete guide to Hims' transition from compounded semaglutide to branded Wegovy through the Novo Nordisk partnership — pricing, timeline, what current patients should do.

Side Effects

How Long Do Semaglutide Side Effects Last? Realistic Timelines by Side Effect

Realistic timelines for every common semaglutide side effect. When nausea, diarrhea, fatigue, and other symptoms improve — based on STEP trial data, not marketing claims.

Patient Guides

How Long Does It Take for GLP-1 to Work?

GLP-1 medications start suppressing appetite within 1–2 weeks, but significant weight loss takes 12+ weeks. Here's the full timeline by drug, dose, and patient type.

Results & Benefits

How Long Does Ozempic Take to Work? (Wegovy & Tirzepatide Too)

Ozempic and Wegovy typically suppress appetite within 1–2 weeks of starting. Meaningful weight loss appears around weeks 4–8. Full results at the highest dose take 12–16+ months. Here is the precise timeline, and what to do if nothing is happening.

Patient Guides

How Long Does Semaglutide Take to Work? A Week-by-Week Guide

Patient Guides

How Much Does Semaglutide Cost in 2026? Brand Name vs. Compounded

Semaglutide costs $936–$1,349/mo brand-name or $129–$199/mo compounded through telehealth. Full price breakdown by provider, insurance, and dose — updated April 2026.

Patient Guides

How Much Does Tirzepatide Cost in 2026? Mounjaro, Zepbound & Compounded

Tirzepatide costs $299–$1,112/mo depending on how you access it. Full breakdown for Mounjaro, Zepbound (including LillyDirect vial pricing), and telehealth compounded options — April 2026.

Patient Guides

GLP-1 Savings Strategies: Complete Optimization Toolkit Guide (2026)

Patient Guides

How to Calculate True GLP-1 Costs: Complete Methodology Guide 2026

Patient Guides

How to Get GLP-1 Medications Covered by Insurance in 2026

Step-by-step guide to getting Wegovy, Zepbound, or Ozempic covered by insurance. Prior auth requirements, appeal strategies, and what to do if you're denied.

Patient Guides

How to Get Orforglipron: Prescription Access, Telehealth, and What to Expect

Orforglipron (Eli Lilly's once-daily oral GLP-1) is now FDA-approved. Here's how to get a prescription through telehealth, which providers carry it, eligibility requirements, and cost.

Insurance & Cost

How to Get Ozempic Online in 2026: Step-by-Step Guide

Step-by-step guide to getting semaglutide online in 2026 — eligibility, telehealth providers, pricing, brand vs compounded, Hims brand-only status, orforglipron option, and red flags to avoid.

Patient Guides

How to Get TRT Online in 2026: Step-by-Step Guide

Patient Guides

How to Maximize GLP-1 Results: 12-Week Optimization Protocol for Enhanced Weight Loss

Insurance & Cost

How to Order and Receive Compounded GLP-1 Medications Online (2026 Guide)

The complete patient guide to ordering compounded GLP-1 medications online — from telehealth consultation to pharmacy verification, receiving, and storage. Includes what is still legal in 2026.

Patient Guides

How to Save Money on GLP-1 Medications in 2026

GLP-1 medications don't have to cost $1,000+/month. This guide covers every legitimate way to reduce your costs — from compounded options to insurance tips, coupons, and subscription models.

Patient Guides

How to Start GLP-1 Treatment: Complete 7-Step Process Guide

Patient Guides

How to Switch GLP-1 Providers Without Losing Progress: Complete Transition Guide

Patient Guides

How to Switch GLP-1 Providers Without Losing Progress

Insurance & Cost

What Is a Compounding Pharmacy — and Why Are They Making GLP-1 Drugs?

Compounding pharmacies were making millions of doses of semaglutide. Here's what they are, why they exist, why GLP-1 compounding became huge, and why it's being shut down.

Patient Guides

HRT Telehealth by State 2026: Which States Can You Get Estrogen or Testosterone Online?

Insurance & Cost

Using HSA and FSA for GLP-1 Medications: Complete Guide

Your HSA or FSA can pay for GLP-1 medications — potentially saving 20-30% through tax advantages. Here's exactly what's eligible, the documentation you need, and how to maximize your savings.

Insurance & Cost

My Insurance Stopped Covering My GLP-1 — What to Do Now

If your insurance just dropped GLP-1 coverage, you have options — and time matters. This guide walks you through the first 48 hours, the appeal process, cash-pay bridge options, and how to avoid a gap in treatment.

Patient Guides

Best Ipamorelin Telehealth Providers 2026: Complete Guide

Side Effects

Is Ozempic Safe? What the Evidence Actually Shows

Evidence-based safety guide for Ozempic (semaglutide) covering 9+ years of clinical data, the SELECT trial 5-year results, thyroid cancer risk clarification, and the complete safety picture as of January 2026.

Patient Guides

How to Maintain Weight Loss After Stopping GLP-1 Medications

Insurance & Cost

Medi-Cal GLP-1 Coverage in 2026: What's Covered, What's Not, and Your Options

Medi-Cal stopped covering Wegovy, Zepbound, and Saxenda for weight loss in 2026. Learn what's still covered, your alternatives, and how to access GLP-1 medications in California.

Patient Guides

Medicare GLP-1 Bridge Program 2026: Complete Preparation Guide

Insurance & Cost

Medicare GLP-1 Coverage in 2026: The Complete Update

The Medicare GLP-1 bridge demonstration is scheduled to launch July 1, 2026. Two CMS pathways, a $50/month copay cap, and a $245 reference price — here's what every Medicare beneficiary needs to know.

Insurance & Cost

Medicare Now Covers GLP-1s for Weight Loss: What Patients Need to Know

Medicare Part D is expected to cover GLP-1 medications for obesity (Bridge program scheduled July 2026) — the biggest access expansion in GLP-1 history. Here's what's covered, what you'll pay, and how to get started.

Patient Guides

Medicare GLP-1 Coverage 2026: Complete Telehealth Provider Guide

Patient Guides

Metformin for Weight Loss: What the Evidence Actually Shows

Complete guide to metformin for weight loss — what clinical evidence shows (2-5% weight loss), how it compares to GLP-1 medications, who it's best for, and how to get it.

Medications

Metformin for Weight Loss: What the Evidence Actually Shows

Honest guide to metformin for weight loss — how it works, what the evidence actually shows (2-5% body weight loss), how it compares to GLP-1 medications, who benefits most (PCOS, prediabetes, budget-constrained patients), and what it costs ($10-30/month).

Patient Guides

MK-677 (Ibutamoren) Telehealth Guide 2026: Providers, Costs & Safety

Patient Guides

Monthly GLP-1 Injections: Once-a-Month Options in Development

Guide to once-monthly GLP-1 injection formulations in development, explaining why monthly dosing could improve adherence but noting no monthly options are FDA-approved as of April 2026. Realistic approval timelines are estimated at 2028-2030 or later.

Patient Guides

Most Affordable GLP-1 Options in 2026: Complete Cost Comparison

Complete guide to the most affordable GLP-1 options in 2026. Compare: orforglipron $149/mo, GoodRx telehealth $39/mo sub, Medicare Bridge $50/mo, Novo $675 list price impact, and more. Real pricing, no 'starting at' ranges.

Patient Guides

MOTS-c Peptide Guide 2026: Metabolic Health, Longevity & Telehealth Providers

Insurance & Cost

Mounjaro Cost Without Insurance in 2026: All Your Options

Mounjaro costs $1,069–$1,112/month at retail without any coverage — and unlike Zepbound, there is no $299/month LillyDirect cash-pay option. If you have commercial insurance, the Lilly Savings Card brings that to $25/month. Medicare patients pay ~$50/month in 2026. Here is every option explained.

Insurance & Cost

Mounjaro Cost Without Insurance in 2026: Real Prices + Savings Options

Mounjaro's retail cash price is $1,069–$1,112/month without insurance — and unlike Zepbound, there is no flat-rate manufacturer cash-pay program. With commercial insurance and the Lilly Savings Card, cost drops to $25/month. Medicare patients pay ~$50/month in 2026.

Insurance & Cost

Mounjaro Coupon & Savings Card Guide 2026: How to Pay Less for Tirzepatide

There is no traditional Mounjaro coupon. What actually reduces your cost is the Lilly Savings Card ($25/mo with commercial insurance), LillyDirect ($299/mo cash-pay), or Lilly Cares patient assistance for low-income patients. This guide covers every option with real eligibility criteria.

Medications

Mounjaro Dose: Complete Schedule, Starting Dose & Titration Guide

Mounjaro starts at 2.5mg weekly and titrates to a target of 5–15mg over 8–20 weeks. Here is the full dose chart, what to do if you can't tolerate an increase, missed dose rules, and how Mounjaro dosing compares to Zepbound.

Patient Guides

Mounjaro Side Effects: What T2D Patients Need to Know (2026)

Complete guide to Mounjaro (tirzepatide) side effects in T2D patients: GI symptoms, hypoglycemia risk, hair loss, pancreatitis warning, and management strategies. Updated April 2026.

Patient Guides

NAD+ Peptide Telehealth: Complete Cost Guide & Provider Options 2026

Medications

Next-Gen Weight Loss Drugs 2026-2026: Pipeline Comparison Guide

Five next-generation weight loss drugs are reshaping the GLP-1 market. Orforglipron is already approved. CagriSema is under FDA review. Retatrutide showed 28.7% weight loss. Here's what patients need to know about each one.

Providers

Noom GLP-1 Guide: Medication + Coaching, Honest Assessment

Noom's GLP-1 program pairs FDA-approved weight loss medication with CBT-based behavioral coaching. That combination has real value — for the right patient. This guide explains who that is, what it costs, and who should look elsewhere.

Patient Guides

Novo-Hims Deal Explained: What It Means for GLP-1 Patients

The Novo Nordisk-Hims settlement (March 9, 2026) means Hims is exiting compounded semaglutide and shifting to branded Wegovy exclusively. What this means for GLP-1 patients.

Insurance & Cost

Novo Nordisk GLP-1 Price Cut: What $675/Month Actually Means for Patients

Novo Nordisk cut the list price of Wegovy and Ozempic by roughly 50% to $675/month. Here's what that actually means for your wallet — and what it doesn't change.

Insurance & Cost

NovoCare Pharmacy Direct: Wegovy Cash Price & How It Works

Novo Nordisk's NovoCare Pharmacy offers Wegovy direct to patients at $499/month cash price. How it works, who qualifies, comparison to telehealth and insurance options.

Patient Guides

How Much Does HRT Cost Online in 2026? Telehealth & Retail Price Guide

Patient Guides

How Much Does TRT Cost Online? A Complete 2026 Price Breakdown

Patient Guides

Oral Wegovy Pill: Complete Guide to the First GLP-1 Weight Loss Tablet

Everything you need to know about the oral Wegovy pill (semaglutide 25mg tablet) — FDA approval, dosing schedule, pricing, where to get it, and how it compares to injectable Wegovy.

Patient Guides

Orforglipron Just Got FDA Approved: Here's How to Get a Prescription

Orforglipron FDA approval guide: eligibility, how to get a prescription, cost ($149/month), telehealth providers, and what to expect in the first month.

Patient Guides

Orforglipron: Lilly's Oral GLP-1 — What Patients Need to Know

Orforglipron — Eli Lilly's oral GLP-1 pill awaiting FDA decision (PDUFA April 10, 2026). Projected $149/month pricing, ATTAIN trial efficacy data, how it compares to oral Wegovy, and what to expect.

Medications

FDA Issued an Orforglipron CRL: What It Means and What Happens Next

The FDA issued a Complete Response Letter for orforglipron on April 10, 2026. A CRL is not a rejection and is not a safety finding. It means the FDA needs more information before it can approve. Here is what happens next and what your treatment options are today.

Patient Guides

Orforglipron Dosing Guide: How to Take It, Titration Schedule & What to Expect

Orforglipron dosing guide: once-daily oral GLP-1 pill with a 12-week titration from 3 mg to 45 mg. How to take it, what's different from injectables, and side effect management.

Patient Guides

Orforglipron Market Tracker: Post-Approval Status, Pricing & Insurance Coverage (April 2026)

Track orforglipron's post-approval market status: $149/mo LillyDirect pricing holds at 11 months, PBM formulary coverage expanding, prescriber adoption patterns, and competitive positioning vs Oral Wegovy.

Patient Guides

Orforglipron FDA Decision Tracker: PDUFA Date, Approval Timeline & What to Expect

The FDA PDUFA date for orforglipron is April 10, 2026. Track the approval status, understand what the decision means, and learn what happens next — for patients, not investors.

Patient Guides

Does Insurance Cover Orforglipron? Coverage Guide for 2026

Orforglipron insurance coverage guide: what to expect from commercial plans and Medicare, how to navigate prior authorization, and what to pay out of pocket if coverage is denied.

Medications

Orforglipron Launch Tracker: What Patients Need to Know Before April 10

Orforglipron FDA decision expected April 10, 2026. What it is, how it compares to injections, which telehealth providers will carry it at $149/mo, and how to prepare now.

Patient Guides

Orforglipron One-Year Review: How the First Oral GLP-1 Changed Weight Loss Treatment

One year after FDA approval, we review orforglipron's real-world impact: $149/mo pricing stability, patient adherence data, market disruption, and what's next for Eli Lilly's oral GLP-1 pill.

Insurance & Cost

Orforglipron Price Guide: What It Costs, Insurance, and How It Compares

Orforglipron PDUFA date is April 10, 2026. If approved, Lilly has disclosed pricing of $149/month through LillyDirect — how it compares to oral Wegovy ($199-$299), projected insurance coverage, and what to expect at launch.

Patient Guides

Orforglipron Real-World Reviews: 1 Year After FDA Approval

Independent analysis of orforglipron patient experiences, side effects, and real-world outcomes 1 year after FDA approval. Updated April 2026.

Patient Guides

Orforglipron Side Effects: What Clinical Trials Show and What to Expect

Complete guide to orforglipron side effects — ATTAIN clinical trial data, GI effect rates, comparisons to other GLP-1s, and management strategies. PDUFA date April 10, 2026.

Patient Guides

How to Switch From Injectable GLP-1 to Orforglipron: A Patient Guide

Switching from injectable semaglutide or tirzepatide to oral orforglipron? ATTAIN-MAINTAIN trial data, dose equivalency, timing, side effects, and what to expect.

Patient Guides

Orforglipron vs. Oral Wegovy: Which GLP-1 Pill Is Right for You?

Comparing orforglipron and oral Wegovy pill head-to-head: weight loss results, pricing, fasting requirements, side effects, and insurance coverage. A decision guide for patients choosing between the two oral GLP-1 options.

Patient Guides

Ozempic Alternatives 2026: Every Option Compared by Cost, Efficacy & Access

Complete guide to every Ozempic alternative in 2026 — Wegovy HD (20.7% weight loss), Zepbound, oral Wegovy, orforglipron (awaiting FDA approval, PDUFA April 10, 2026), non-GLP-1 prescriptions, and pipeline drugs. Updated pricing, efficacy, insurance coverage, and a decision framework for your situation.

Side Effects

Ozempic and Alcohol: Safety, Interactions, and What Your Prescriber Won't Always Tell You

Ozempic does not have a hard contraindication with alcohol, but the combination carries specific risks — hypoglycemia in T2D patients, amplified nausea, and potential liver concerns during active weight loss. Here's what the clinical evidence actually shows.

Patient Guides

Ozempic Before Surgery: When to Stop GLP-1 Medications and What to Know

When should you stop Ozempic, Wegovy, or Mounjaro before surgery? Current 2024-2025 guidelines on GLP-1 aspiration risk, medication hold timelines, and patient action steps.

Patient Guides

Ozempic Bloating: Why It Happens and How to Reduce It

Bloating on Ozempic is caused by slowed gastric emptying and gas accumulation. Learn why it happens, how long it lasts, and evidence-based ways to reduce it.

Patient Guides

Ozempic Body Changes: What to Expect During GLP-1 Weight Loss

What body changes happen on Ozempic and other GLP-1 medications? Facial volume loss, loose skin, butt changes, and body composition shifts explained with clinical data.

Insurance & Cost

Ozempic Cost Without Insurance in 2026: Real Prices + Savings Options

Ozempic's retail price without insurance runs $935–$1,000/month. But there are real paths to lower costs — from the Novo Nordisk savings card to compounded semaglutide at $129–249/month.

Insurance & Cost

Ozempic Coupon & Savings Guide 2026: How to Pay Less for Semaglutide

Every way to save on Ozempic in 2026 — Novo Nordisk savings card ($25/mo for commercially insured), Medicare $50 copay cap, Wegovy HD savings card, patient assistance, and what to do if you actually want semaglutide for weight loss.

Side Effects

Ozempic Diarrhea: Why It Happens, How Long It Lasts, and What Helps

Diarrhea is among the most common GI side effects of Ozempic and Wegovy — affecting 15–30% of patients. Here's why it happens, how long it typically lasts, and evidence-based strategies to manage it without stopping your medication.

Patient Guides

Ozempic Dosing Schedule: Starting Dose, Titration, and How to Take It

Patient Guides

Ozempic Face: What It Is, Why It Happens, and What You Can Do

What is Ozempic face? Why GLP-1 weight loss causes facial volume loss, who's most at risk, and evidence-based strategies to prevent or treat it.

Patient Guides

Ozempic Fatigue: Why It Happens, How Long It Lasts, and What Helps

Fatigue is a real but underreported Ozempic side effect. Learn the 5 mechanisms behind it, what SUSTAIN data shows, and what actually helps — including a critical T2D safety note.

Patient Guides

Foods to Avoid on Ozempic: What to Eat and What Makes Side Effects Worse

No foods are strictly prohibited on Ozempic, but several categories consistently worsen side effects. Understanding the GI mechanism helps — and protein-first eating matters more than any specific food restriction.

Patient Guides

Ozempic Hair Loss: Does It Happen, Why, and What You Can Do

Does Ozempic cause hair loss? SUSTAIN trial data, T2D-specific context, timeline, and evidence-based prevention strategies.

Side Effects

Ozempic Headache: Why It Happens and How to Get Relief

Headaches on Ozempic are real and common — but usually traceable to three specific causes, all manageable. Most resolve within the first few weeks of treatment.

Patient Guides

How to Inject Ozempic: Step-by-Step Pen Guide

Patient Guides

Ozempic Long-Term Side Effects: What the Research Actually Shows

Patient Guides

Ozempic and Muscle Loss: What the Data Shows (And What You Can Do About It)

Does Ozempic cause muscle loss? SUSTAIN trial data, what lean mass actually means, and evidence-based strategies to preserve muscle while on semaglutide.

Patient Guides

Ozempic Nausea: Why It Happens, How Long It Lasts, and What Helps

Nausea is the most common Ozempic side effect. Learn why semaglutide causes nausea, what the SUSTAIN trial data shows, and which strategies actually reduce it.

Insurance & Cost

How to Get an Ozempic Prescription Online in 2026

You can get an Ozempic (or Wegovy) prescription online through telehealth in 24–48 hours. Here is exactly how it works, which providers are fastest, what it costs, and the one distinction that matters: for weight loss, most providers prescribe Wegovy — not Ozempic.

Patient Guides

Ozempic and Pancreatitis: What the Research Actually Shows (2026)

Ozempic carries a labeled pancreatitis risk. Here's what the clinical data shows, who's at higher risk, warning symptoms, and what to do if you're concerned.

Patient Guides

Ozempic Plateau: Why Weight Loss Stalls and What Your Options Are

Ozempic's 2mg dose ceiling is the central constraint most T2D patients hit at plateau. Weight loss stalls are physiologically expected at 6–12 months. Here's why it happens and what your options are.

Patient Guides

Ozempic and Pregnancy: What You Need to Know About Fertility and Safety

Ozempic is contraindicated in pregnancy. Learn about the 'Ozempic babies' phenomenon, washout recommendations before conception, and what the fertility research actually shows.

Patient Guides

Ozempic Shortage Update 2026: Is It Over, and What Happened to Compounded Semaglutide?

Results & Benefits

Ozempic, Wegovy & Tirzepatide Before and After: Real Results and What to Expect

Ozempic: ~9.6% weight loss at 40 weeks. Wegovy: 14.9% at 68 weeks (50% of patients lose 15%+). Tirzepatide: 22.5% at 72 weeks (63% lose 20%+). Here is what before and after actually looks like in clinical data, month by month.

Patient Guides

Ozempic Weight Loss Results: What Clinical Trials Actually Show

Patient Guides

Peptide Side Effects: Complete Safety Guide 2026

Patient Guides

Peptide Therapy for Anti-Aging: What You Need to Know

Medications

Phentermine for Weight Loss 2026: The Complete Guide to America's Most Prescribed Diet Pill

Complete guide to phentermine for weight loss — how it works, clinical results (5-7% body weight), side effects, controlled substance status, pricing ($15-50/month for generic), the 12-week duration controversy, and honest comparison to GLP-1 medications like Wegovy and Zepbound.

Patient Guides

Prescription Weight Loss Pills 2026: Every FDA-Approved Oral Medication Compared

Every prescription weight loss pill compared — oral GLP-1s (oral Wegovy, orforglipron), non-GLP-1 pills (Contrave, Qsymia, phentermine, Xenical), and off-label options (metformin, topiramate). No injections. Efficacy, pricing, side effects, insurance coverage, and how to choose the right pill for your situation.

Patient Guides

PT-141 for Sexual Health: Complete Provider Options & Cost Guide 2026

Medications

Qsymia Guide 2026: The Phentermine/Topiramate Combination — Weight Loss, Risks & GLP-1 Comparison

Complete guide to Qsymia (phentermine/topiramate ER) — how it works, clinical trial results (8-10% weight loss), REMS program requirements, controlled substance status, cognitive side effects, pricing ($200-250/month), and honest comparison to GLP-1 medications like Wegovy and Zepbound.

Patient Guides

7 Questions to Ask Before Choosing a Peptide Provider

Patient Guides

5 Red Flags When Choosing a GLP-1 Telehealth Provider

Patient Guides

Patient Guides

Retatrutide: The Triple-Agonist GLP-1 That Could Change Everything

Complete guide to retatrutide — Eli Lilly's triple-agonist (GLP-1/GIP/glucagon) with 28.7% weight loss in trials. Clinical data, how it compares, and when it might be available.

Patient Guides

Retatrutide Cost: What Will Eli Lilly's Triple-Agonist Cost When It Launches?

No official pricing exists for retatrutide — it hasn't been FDA-approved. Based on Lilly's existing portfolio, expect a list price of $1,000-1,500/mo with LillyDirect pricing potentially reducing that to $299-449/mo. Here's what we know, what we can project, and how to prepare.

Patient Guides

Retatrutide Dosing Guide: Titration Schedule, Dose Steps & What to Expect

Complete retatrutide dosing guide based on TRIUMPH Phase 3 clinical trial protocols. Titration schedule from 1mg to 12mg, dose adjustments, side effects at each step, and comparison to semaglutide and tirzepatide dosing.

Medications

Retatrutide Patient Guide: Should You Wait for the Most Effective GLP-1?

Retatrutide produced 28.7% weight loss in TRIUMPH-4 — the highest ever recorded. But it's not available yet. This guide helps patients decide: wait for retatrutide, or start treatment now with what's available?

Patient Guides

Retatrutide Side Effects: What Clinical Trials Show About Safety

Complete guide to retatrutide side effects from TRIUMPH Phase 3 clinical trials. Covers GI effects, dysesthesia (20.9%), serious risks, and how retatrutide compares to semaglutide and tirzepatide.

Medications

Saxenda Guide 2026: The First-Gen GLP-1 — How It Compares to Wegovy and Zepbound

Complete guide to Saxenda (liraglutide) — the original FDA-approved GLP-1 for weight loss. How it compares to newer GLP-1s like Wegovy and Zepbound, typical results (~8% body weight loss), the generic liraglutide option (~$230/month), dosing, side effects, and who it's still a fit for in 2026.

Patient Guides

Semaglutide: Complete Guide to Ozempic, Wegovy & Compounded Options

Everything about semaglutide in one place: how it works, brand vs. compounded versions, dosing, side effects, real costs, and where to get it online.

Patient Guides

Semaglutide Dosing Guide: Every Formulation, Every Dose Step

Complete semaglutide dosing and titration guide covering Wegovy, Ozempic, oral Wegovy, and compounded formulations. Exact schedules, what to expect at each dose, and when to adjust.

Side Effects

Semaglutide Long-Term Side Effects: What 5 Years of Data Actually Shows

What happens when you take semaglutide for years? The SELECT trial followed 17,600+ patients for up to 5 years. Here is what the long-term safety data actually shows.

Patient Guides

Does Semaglutide Affect Male Fertility? What the Research Shows (2026)

Does semaglutide (Ozempic/Wegovy) affect male fertility or sperm count? We break down the 2025 research, what weight loss means for male fertility, and guidance for men trying to conceive.

Side Effects

Semaglutide Side Effects: The Complete Guide for 2026

Every semaglutide side effect explained with clinical trial data. Common GI effects, rare serious risks, long-term safety, hair loss, cancer concerns — and how to manage them.

Patient Guides

Semaglutide vs Tirzepatide: Complete 2026 Decision Guide

Tirzepatide produces 47% greater weight loss than semaglutide in the SURMOUNT-5 head-to-head trial. But semaglutide has proven cardiovascular benefits, new high-dose and oral options in 2026, and lower costs across most providers. This guide covers every dimension of the comparison so you can choose the right medication for your situation.

Patient Guides

Semax and Selank: Cognitive Peptides Guide 2026 — Providers & Protocols

Patient Guides

Best Sermorelin Telehealth Providers 2026: Complete Guide

Patient Guides

GLP-1 Surgery Guidelines 2026: SPAQI Perioperative Consensus Explained

The SPAQI GLP-1 perioperative consensus explained for patients and providers: hold timing, aspiration risk, oral vs. injectable differences, and what to tell your surgical team.

Patient Guides

Spring Weight Loss Momentum: 8-Week GLP-1 Summer Prep Timeline

Patient Guides

Starting a GLP-1 Medication in 2026: What You Need to Know

Everything new GLP-1 patients need to know in 2026: orforglipron at $149/mo, Wegovy HD, Medicare $50 copay, CagriSema decision pending, brand-only market, and how to choose the right provider.

Patient Guides

What Happens When You Stop Taking Ozempic: Weight Regain, Timeline, and What to Do

Most patients regain significant weight within 6–12 months of stopping Ozempic. This guide covers the physiology, the honest timeline, what helps minimize regain, and what your options are when stopping is necessary.

Patient Guides

What Happens When You Stop Taking Wegovy: Weight Regain, Timeline, and What to Do

Most patients regain significant weight within 6–12 months of stopping Wegovy. This guide covers what the STEP trial data actually shows, the honest regain timeline, what helps minimize rebound, and what your options are when stopping is necessary.

Patient Guides

Summer Weight Loss Prep with GLP-1: Complete Timeline Guide

Patient Guides

Survodutide: Boehringer's Dual GLP-1/Glucagon Agonist for Obesity & MASH

Complete guide to survodutide — Boehringer Ingelheim's dual GLP-1/glucagon receptor agonist. Phase 2 results (83% MASH improvement), Phase 3 trials, FDA Breakthrough Therapy, and realistic approval timeline.

Patient Guides

Switching Between GLP-1 Medications: A Complete Transition Guide

How to safely switch between GLP-1 medications — semaglutide to tirzepatide, injectable to oral, compounded to branded. Dosing equivalences, transition protocols, and what to expect.

Patient Guides

Best TB-500 Telehealth Providers 2026: Injury Recovery Peptide Guide

Patient Guides

Telehealth Oral vs Injectable GLP-1 Providers 2026: Complete Provider Comparison

Patient Guides

Telehealth vs. In-Person for GLP-1 Medications: Which Is Right for You?

Telehealth has made GLP-1 medications dramatically more accessible — but is it the right choice for everyone? We compare cost, clinical depth, convenience, and outcomes to help you decide between online and in-person weight loss care.

Patient Guides

Telehealth vs In-Person for GLP-1: Which Is Better for You?

Should you get GLP-1 medications through telehealth or in-person? Compare costs, clinical depth, medication access, insurance coverage, and convenience to find the right fit.

Patient Guides

Best Tesamorelin Telehealth Providers 2026: Complete Guide

Patient Guides

Testosterone Therapy for Women: What It Does, Who It Helps, and How to Get It

Patient Guides

Thymosin Alpha-1 (TA-1) Telehealth Providers Guide 2026

Patient Guides

Tirzepatide: Complete Guide to Mounjaro, Zepbound & What You Need to Know

Everything about tirzepatide in one place: how it works, Mounjaro vs. Zepbound, dosing protocols, weight loss data, costs, side effects, and where to access it.

Patient Guides

Tirzepatide Dosing Guide: Complete Titration Schedule, Adjustments & What to Expect

Complete tirzepatide dosing guide covering the FDA titration schedule for Mounjaro and Zepbound, compounded dosing, side effect management, missed doses, and what to expect at each dose level.

Patient Guides

How to Get Tirzepatide Online: Step-by-Step Patient Guide (2026)

Learn how to get a tirzepatide prescription online in 2026. Covers eligibility, best telehealth providers (Ro, Found, Henry Meds), real pricing, and what to expect at each step.

Insurance & Cost

Tirzepatide Prior Authorization Guide: Mounjaro & Zepbound 2026

Medications

Tirzepatide Side Effects: Complete Guide to What to Expect and How to Manage Them

Tirzepatide's most common side effects are gastrointestinal — nausea, diarrhea, vomiting, and constipation — and for most patients they are temporary, peaking during dose escalation and fading over weeks. This guide covers rates from SURMOUNT-1 by dose tier, serious warnings explained plainly, and strategies that actually work.

Patient Guides

Is Tirzepatide Better Than Semaglutide? What the SURMOUNT-5 Trial Found

Patient Guides

TRT Side Effects: The Complete Guide

Insurance & Cost

TrumpRx and GLP-1 Access: What Patients Need to Know

What is TrumpRx and how does it affect GLP-1 access? Nonpartisan explainer of the government portal connecting patients to manufacturer medication discounts.

Insurance & Cost

Does United Healthcare Cover GLP-1 Medications? 2026 Guide

Patient Guides

Wegovy and Alcohol: What the Clinical Evidence Shows

Can you drink alcohol on Wegovy? No hard contraindication, but specific risks — GI amplification, pancreatitis for heavy drinkers, and caloric impact. What to know.

Insurance & Cost

Wegovy Cost Without Insurance in 2026: Real Prices + Savings Options

Wegovy's retail price without insurance is approximately $1,349/month. But there are real paths to lower costs — from the Novo Nordisk savings card to oral Wegovy at $199–299/month through telehealth.

Insurance & Cost

Wegovy Coupon & Savings Guide 2026: How to Pay Less for Semaglutide

Every way to save on Wegovy in 2026 — Novo Nordisk savings card (including Wegovy HD), Medicare $50 copay (Bridge program scheduled July 2026), oral Wegovy pricing, orforglipron at $149/mo (pending FDA approval April 10), patient assistance, and HSA/FSA strategies.

Medications

Wegovy Dose: Complete Schedule, Starting Dose & Titration Guide

Wegovy starts at 0.25mg weekly and titrates to 2.4mg over 16 weeks. Here is the complete schedule, what to do if you can't tolerate a dose increase, missed dose rules, and how Wegovy's dosing differs from Ozempic.

Patient Guides

Wegovy and Hair Loss: What Patients at 2.4mg Should Know

Alopecia was reported in 3.0% of Wegovy patients in STEP 1 versus 0.9% on placebo. The cause is telogen effluvium driven by caloric restriction — not a direct drug effect. Timeline, prevention, and when to escalate.

Medications

Wegovy 7.2mg (Wegovy HD): Complete Guide to Higher-Dose Semaglutide

Wegovy 7.2mg (Wegovy HD) delivers 20.7% weight loss — the highest semaglutide dose available. Dosing schedule, pricing, side effects, and who should escalate to 7.2mg.

Patient Guides

Wegovy Injection Site: Where to Inject, How to Rotate & Step-by-Step Guide

Wegovy can be injected in the abdomen (2 inches from navel), outer thigh, or upper arm. Site rotation every week prevents lipohypertrophy — lumps that impair drug absorption. Here is the full technique, rotation protocol, and what to do if something goes wrong.

Patient Guides

Wegovy & Ozempic Savings: Every Coupon, Discount, and Assistance Program (2026)

Complete guide to reducing out-of-pocket costs for Wegovy and Ozempic. Covers NovoCare savings cards, patient assistance programs, pharmacy discount strategies, and how to maximize savings with or without insurance.

Insurance & Cost

Wegovy & Ozempic Savings Cards, Coupons & Discounts 2026: Complete Guide

Updated for 2026: Wegovy and Ozempic are now $675/mo list price after Novo Nordisk's January price cut. Here's every savings path — savings cards, Medicare $50 copay cap, patient assistance, and when to consider switching to orforglipron at $149/mo.

Patient Guides

Wegovy and Pregnancy: Safety, Fertility Effects & What Doctors Recommend

Wegovy is contraindicated in pregnancy. Learn about washout timing before conception, the fertility-restoring effect of weight loss, and what to do if you become pregnant while on Wegovy.

Patient Guides

Wegovy Side Effects: The Complete 2026 Guide

Every Wegovy side effect with STEP trial frequencies, from common GI effects to rare risks. What to expect, when to call your doctor, and how to minimize discomfort.

Results & Benefits

Wegovy Weight Loss Results: STEP Trial Data, Realistic Timelines & What to Expect

STEP 1 trial: 14.9% average body weight loss at 68 weeks. 45% of participants lost 15%+ of body weight. Here is what the full dataset looks like, when to expect results, and how Wegovy compares to tirzepatide.

Patient Guides

Weight Loss Shots 2026: Every Injectable Medication Compared

Every weight loss injection compared in one place — Wegovy, Zepbound, Saxenda, Ozempic, Mounjaro, and compounded options. How they work, how much weight you lose, what they cost, what the injection actually feels like, and how shots compare to pills.

Patient Guides

What Are Peptides? A Complete Guide for 2026

Results & Benefits

What Happens When You Stop Taking GLP-1 Medications: The Weight Regain Reality

The reality of stopping GLP-1 medications — STEP 1 extension shows two-thirds of weight regained within a year. What the data says, why it happens, and strategies for maintaining results.

Patient Guides

What is Semaglutide: Complete GLP-1 Guide 2026

Patient Guides

What is Tirzepatide: Dual-Hormone Weight Loss Medication Guide 2026

Patient Guides

What to Do When GLP-1 Stops Working: Breaking Through Weight Loss Plateaus

Patient Guides

What to Eat on Ozempic: A Practical Food Guide

Insurance & Cost

When Will Generic Wegovy Be Available? Timeline, Patents & Alternatives

When will generic semaglutide (Wegovy) be available? Patent analysis, biosimilar timeline, and what you can do now to save on GLP-1 meds.

Patient Guides

Who Qualifies for GLP-1 Medications: Eligibility Criteria Explained (2026)

Complete guide to GLP-1 medication eligibility: BMI thresholds, qualifying health conditions, contraindications, and how online providers evaluate patients. Updated April 2026.

Insurance & Cost

Zepbound Coupon & Savings Guide 2026: How to Pay Less for Tirzepatide

Every way to save on Zepbound (tirzepatide) in 2026 — Lilly savings card, LillyDirect cash-pay, Medicare copay cap, patient assistance, and HSA/FSA strategies. Real numbers, clear eligibility criteria.

Patient Guides

Zepbound Dosing Schedule: Complete Guide (2026)

Insurance & Cost

Zepbound Price Guide 2026: What It Actually Costs by Channel

Zepbound costs anywhere from $25/month with insurance to $1,060/month at retail. LillyDirect holds at $299/mo through Dec 2026. Medicare Bridge is scheduled for $50/mo starting July 1, 2026. Full breakdown of every channel.

Patient Guides

Zepbound Side Effects: What to Expect, How Long They Last

Complete guide to Zepbound (tirzepatide) side effects: GI symptoms, hair loss, injection site reactions, serious warnings, and how to manage them during titration.

Patient Guides

Zepbound Weight Loss Results: SURMOUNT Trial Data, Timeline & What to Expect

Insurance & Cost

Zepbound Without Insurance: Cost & Options Guide 2026

Zepbound without insurance costs $299-$449/mo through LillyDirect's cash-pay vial program — about 40% less than retail pens. Here's every option for uninsured patients in April 2026, including patient assistance and when prior authorization is worth pursuing.

Get weekly GLP-1 pricing updates

We track prices so you don't have to.

No spam. Unsubscribe anytime.

50+ providers trackedUpdated weekly100% independent

Ready to Find Your Match?

Answer a few quick questions and we’ll match you with the right provider and medication for your goals.

Take the Quiz →Compare Providers